FTSE MIB
33.876,80 -4,70 (-0,01%) Dow Jones
37.775,38 +22,07 (+0,06%) Nasdaq
15.601,50 -81,87 (-0,52%) Nikkei 225
37.068,35 -1.011,35 (-2,66%) Petrolio
82,17 -0,56 (-0,68%) Bitcoin EUR
61.199,90 +2.860,92 (+4,90%)
Apellis Pharmaceuticals, Inc. (APLS)
Preborsa:
| Chiusura precedente | 48,03 |
| Aperto | 47,91 |
| Denaro | 47,47 x 200 |
| Lettera | 47,55 x 200 |
| Min-Max giorno | 46,40 - 48,83 |
| Intervallo di 52 settimane | 19,83 - 94,75 |
| Volume | |
| Media Volume | 1.361.108 |
| Capitalizzazione | 5,729B |
| Beta (5 anni mensile) | 0,89 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -4,45 |
| Prossima data utili | 02 mag 2024 - 06 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 82,13 |
GlobeNewswireApellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved the grant of equity awards to seven new employees with a grant date of October 2, 2023, as equity inducement awards outside of the company's 2017 Stock Incentive Plan (but under the terms of the 2020 Inducement Stock Incentive Plan) and material to the employees’ acceptance of employment with the com
- GlobeNewswire
Apellis Announces Preliminary U.S. Net Revenues of Approximately $74 Million for SYFOVRE® (pegcetacoplan injection) in the Third Quarter of 2023
Continued strong demand, with more than 100,000 vials (commercial and sample) distributed to date; growth in week-over-week demand returned starting in AugustPermanent J-code effective as of October 1, and more than 95% of all Medicare payers now covering SYFOVREUp to 45% reduction of nonsubfoveal GA lesion growth observed between Months 24-30 compared to projected sham in the GALE extension studyEstimated rate of retinal vasculitis continues to be rare at 0.01% per injection WALTHAM, Mass., Oct
GlobeNewswireApellis Announces U.S. FDA Approval of the EMPAVELI® Injector, a Device to Streamline Self-Administration
EMPAVELI® Injector EMPAVELI® Injector Compact, single-use, on-body injector designed to enhance the patient experience of administering EMPAVELI® (pegcetacoplan) WALTHAM, Mass., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Food and Drug Administration (FDA) has approved the EMPAVELI® Injector. The EMPAVELI Injector is a compact, single-use, on-body device designed to enhance self-administration of EMPAVELI (pegcetacoplan), which is
